Immune-related adverse events, survival outcomes, and next steps in patients with stage III melanoma: real-world experience at a National Cancer Institute-designated Comprehensive Cancer Center.

Oncologist · 2025 · PMC12712989 · PMID 41296683

Europe PMC DOI

hedged sentence

0.4038

closest p · 8.1× alpha

0.4038

boldest claim

The sentences

a nonsignificant trendP = .4038not close (p > 0.1)

Compared to patients who did not resume therapy after a pause, those who did resume therapy had a nonsignificant trend toward improved OS (HR = 0.517, CI: 0.110-2.436, P = .4038; Figure S1 , see online supplementary material for a color version of this figure).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.